Analysts Issue Forecasts for Cytosorbents FY2024 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Equities researchers at HC Wainwright decreased their FY2024 earnings per share estimates for Cytosorbents in a report released on Monday, November 11th. HC Wainwright analyst S. Lee now anticipates that the medical research company will earn ($0.30) per share for the year, down from their prior forecast of ($0.29). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Cytosorbents’ Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.14) EPS and FY2027 earnings at ($0.12) EPS.

Cytosorbents (NASDAQ:CTSO) last released its earnings results on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $9.73 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. During the same period in the prior year, the company earned ($0.14) EPS.

Several other research firms have also weighed in on CTSO. EF Hutton Acquisition Co. I raised shares of Cytosorbents to a “strong-buy” rating in a report on Monday, July 29th. StockNews.com started coverage on shares of Cytosorbents in a research report on Sunday. They set a “hold” rating on the stock.

Cytosorbents Price Performance

Shares of Cytosorbents stock opened at $0.93 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.71 and a current ratio of 1.97. The firm’s 50-day simple moving average is $1.13 and its 200-day simple moving average is $1.01. The firm has a market cap of $50.63 million, a P/E ratio of -2.57 and a beta of 0.56. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $2.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CTSO. CM Management LLC raised its holdings in Cytosorbents by 3.0% during the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after buying an additional 25,000 shares during the period. Sargent Investment Group LLC lifted its position in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after acquiring an additional 67,181 shares in the last quarter. Atomi Financial Group Inc. bought a new position in Cytosorbents during the 3rd quarter worth about $51,000. Finally, Avenir Corp raised its stake in shares of Cytosorbents by 4.0% in the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after purchasing an additional 121,294 shares during the period. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.